MEDP vs PCVX
Medpace vs Vaxcyte, Inc. — AI-powered side-by-side comparison
VS
PCVX
Vaxcyte, Inc.
67
Buy
| Metric | MEDP | PCVX |
|---|
| AI Score |
64
|
67
|
| Price |
$596.78
|
$59.60
|
| P/E Ratio |
34.82×
|
-7.75×
|
| ROE |
98.3%
|
-28.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.8%
|
0.0%
|
| Debt / Equity |
0.28×
|
0.04×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
72.1
|
65.6
|
| Beta |
1.151
|
1.21
|
| Expected Upside |
+3.0%
|
+4.2%
|
AI Committee View
Current Innellis committee reasoning for MEDP versus PCVX.
PCVX leads by 3 points.
PCVX scores 67/100 (Buy) versus MEDP at 64/100 (Buy).
MEDP Committee View
67% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 34.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.2 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- RSI at 72 is in overbought territory — Technical
PCVX Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -37.6% -- cheap may mean cheap for a reason — Value
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical